These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39093262)

  • 1. Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease: A Pooled Analysis of the ORION-10 and ORION-11 Randomized Trials.
    Wright RS; Ray KK; Landmesser U; Koenig W; Raal FJ; Leiter LA; Conde LG; Han J; Schwartz GG
    Mayo Clin Proc; 2024 Jul; ():. PubMed ID: 39093262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
    J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials.
    Koenig W; Conde LG; Landmesser U; Leiter LA; Ray KK; Schwartz GG; Wright RS; Han J; Raal FJ
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):493-503. PubMed ID: 36550348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11.
    Koenig W; Ray KK; Landmesser U; Leiter LA; Schwartz GG; Wright RS; Conde LG; Han J; Raal FJ
    Am J Prev Cardiol; 2023 Jun; 14():100503. PubMed ID: 37252442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.
    Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D
    S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18.
    Huo Y; Lesogor A; Lee CW; Chiang CE; Mena-Madrazo J; Poh KK; Jeong MH; Maheux P; Zhang M; Wei S; Han Y; Li Y
    JACC Asia; 2024 Feb; 4(2):123-134. PubMed ID: 38371290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
    Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials.
    Leiter LA; Raal FJ; Schwartz GG; Koenig W; Ray KK; Landmesser U; Han J; Conde LG; Wright RS
    Diabetes Obes Metab; 2024 Aug; 26(8):3223-3237. PubMed ID: 38757725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plain language summary of results from ORION-10 and ORION-11: two studies to learn how well inclisiran works in people with high cholesterol.
    Ray KK; Wright RS
    Future Cardiol; 2023 Mar; 19(4):175-184. PubMed ID: 37282500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.
    Wright RS; Raal FJ; Koenig W; Landmesser U; Leiter LA; Vikarunnessa S; Lesogor A; Maheux P; Talloczy Z; Zang X; Schwartz GG; Ray KK
    Cardiovasc Res; 2024 Oct; 120(12):1400-1410. PubMed ID: 38753448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
    Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
    Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP;
    Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
    Ray KK; Kallend D; Leiter LA; Raal FJ; Koenig W; Jaros MJ; Schwartz GG; Landmesser U; Garcia Conde L; Wright RS;
    Eur Heart J; 2022 Dec; 43(48):5047-5057. PubMed ID: 36331315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials.
    Landmesser U; Koenig W; Leiter LA; Raal FJ; Ray KK; Wright RS; Han J; Conde LG; Schwartz GG
    Atherosclerosis; 2023 Dec; 386():117354. PubMed ID: 38016401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the effect of inclisiran on hypercholesterolemia and primary prevention of cardiovascular disease: the NHANES 1999-2018 study.
    Li H; Zhao S; Wu J; Han J; Xu Y; Shi S; Zhang Y
    Lipids Health Dis; 2024 Sep; 23(1):313. PubMed ID: 39334296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
    Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A
    Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.
    Desai NR; Campbell C; Electricwala B; Petrou M; Trueman D; Woodcock F; Cristino J
    Am J Cardiovasc Drugs; 2022 Sep; 22(5):545-556. PubMed ID: 35595929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.
    Ray KK; Stoekenbroek RM; Kallend D; Nishikido T; Leiter LA; Landmesser U; Wright RS; Wijngaard PLJ; Kastelein JJP
    JAMA Cardiol; 2019 Nov; 4(11):1067-1075. PubMed ID: 31553410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials.
    Ray KK; Raal FJ; Kallend DG; Jaros MJ; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Lawrence D; Friedman A; Garcia Conde L; Wright RS;
    Eur Heart J; 2023 Jan; 44(2):129-138. PubMed ID: 36331326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.